12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eniluracil: Interim Phase II data

Interim data from 122 evaluable patients who had previously been treated with an anthracycline and taxane in the open-label, international Phase II AHX-03-202 trial showed that once-weekly 40 mg oral eniluracil for the first 3 weeks of a 4-week cycle plus 5-fluorouracil (5-FU) and leucovorin led to an overall response rate (ORR) of 25%, including 1 complete response and...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >